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Context: Active surveillance of primary congenital hypothyroidism (CH) in a multi-ethnic 
population with established newborn bloodspot screening.  
Objective: To estimate performance of newborn screening for CH at different test 
thresholds; to calculate incidence of primary CH. 
Design: Prospective surveillance undertaken from June 2011 to June 2012 with three-year 
follow-up of outcomes. Relative likelihood ratios (rLRs) estimated to compare bloodspot 
thyroid-stimulating hormone (TSH) test thresholds of 6mU/L and 8mU/L, with the nationally 
recommended standard of 10mU/L for a presumptive positive result.   
Setting: UK National Health Service 
Patients: Clinician notification of children aged under five years investigated following 
clinical presentation or presumptive positive screening result.   
Main outcome measure(s): Permanent primary CH status determined by clinician report of 
continuing thyroxine requirement at three-year follow-up. 
Results: 629 newborns (58.3% girls; 58.7% white ethnicity) were investigated following 
presumptive positive screening result and 21 children (52.4% girls; 52.4% white) after 
clinical presentation; 432 remained on treatment at three-year follow-up. Permanent CH 
incidence was 5.3 (95%CI 4.8, 5.8) per 10,000 infants. Using locally-applied thresholds, 
sensitivity, specificity and positive predictive value were 96.76%, 99.97% and 66.88% 
respectively. Compared with TSH threshold of 10mU/L, positive rLRs for 8mU/L and 
6mU/L were 1.20 (95%CI 0.82, 1.75) and 0.52 (95%CI 0.38, 0.72), and negative rLRs 0.11 
(95%CI 0.03, 0.36) and 0.11 (95%CI 0.06, 0.20) respectively.  
Conclusions: Screening programme performance is good, however a TSH threshold of 
8mU/L appears superior to the current national standard (10mU/L) and requires further 
evaluation. Further research should explore the implications of transient CH for screening 
policy.  
Newborn bloodspot screening for primary congenital hypothyroidism was assessed at different test 
thresholds. Lowering the national threshold should improve performance of the UK screening 
programme. 
Introduction 
Primary congenital hypothyroidism (CH) affects around 1 in 2000 children born in the United 
Kingdom (UK) each year. It is estimated that 8-28% of children presenting clinically will 
develop severe intellectual disability, defined as an IQ <70.1 Newborn screening to identify 
those with CH enables timely thyroxine replacement therapy and potentially prevents or 
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mitigates this disability.2, Newborn screening was introduced in the UK in 1981 and is 
currently based on whole blood thyroid stimulating hormone (TSH) concentrations measured 
in dried bloodspots collected 5 days postnatally.3  Secular increases in the proportion of 
babies with presumptive positive screening results1 may reflect a number of factors, including 
increasing ethnic diversity4, changes in maternal iodine status5,6, and reduction over time in 
the lower limit of TSH threshold used to define a presumptive positive result reflecting 
technological advances in laboratory measurement.1,7   
The UK national standards recommend confirmatory diagnostic testing in all infants with 
screening bloodspot TSH (whole blood) ≥20mU/L, or ≥10mU/L after repeat testing for 
borderline results (Table 1), however in practice there is variability in TSH thresholds for 
technological and historical reasons1 and the current performance of the national programme has 
not been appraised. At the time of this study, 12 of the 16 UK newborn screening laboratories 
employed a TSH threshold below the recommended national standard, largely due to 
concerns about false negative results. This provided a rare opportunity to evaluate screening 
test performance at different TSH thresholds within an existing national programme 
involving a multi-ethnic population of 700,000 births per year. 
We carried out a prospective UK-wide active surveillance study to identify all confirmed 
diagnoses of primary CH in children aged under five years, regardless of screening results.  
As CH may be transient in the early years, we obtained reports of outcomes in notified 
infants after diagnosis and with expert advice from paediatric endocrinologists, developed 
and applied standardised criteria for defining ‘confirmed’ and ‘probable’ CH status from 
clinician reports at three year follow-up. To inform future screening policy, we assessed 
incremental changes in the detection rate, false positive rate and likelihood ratio of two 
alternatives to the current recommended threshold of ≥10mU/L for defining a presumptive 
positive screening result (≥8mU/L or ≥6mU/L). 
Materials and Methods 
Ascertainment of cases 
Children with newly diagnosed CH were identified by active surveillance through the British 
Paediatric Surveillance Unit (BPSU) national clinical paediatric surveillance system and 
through a concurrent laboratory reporting system, involving all 16 UK newborn screening 
laboratories. Secondary and tertiary care paediatricians, and laboratory directors, notified 
monthly all children meeting the reporting case definition (Table 1) and full clinical details 
were obtained from the notifying clinician and laboratory using online questionnaires.8 
Laboratory and clinician notifications were matched using birth date, National Health Service 
(NHS) number or equivalent, sex and postcode district. If a case had not been reported by 
both sources, we asked paediatricians or laboratories to complete a questionnaire or provide 
further clinical details.  
Follow up and outcome adjudication 
All children were followed up annually using online or postal questionnaires sent to 
clinicians until one of the following endpoints: completion of three years follow up, death, 
CH confirmed, discharged from/lost to clinician care. Collected data included details of 
screening and diagnostic test results, clinical presentation and management.  
An independent expert panel, comprising two paediatric endocrinologists and one 
screening laboratory director, reviewed every child’s de-identified data to determine (1) 
eligibility for study inclusion and (2) outcome at three years. Children had confirmed 
permanent CH at three years if a persisting requirement for thyroxine was confirmed by a 
trial off therapy (withdrawal of thyroxine replacement therapy and re-evaluation of thyroid 
function tests to confirm or exclude CH), OR radioisotope or ultrasound scan results 
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confirming thyroid agenesis or ectopic thyroid, OR continuing requirement for ‘high dose’ 
levothyroxine (≥50mcg per day) indicated by regular review of thyroid function by 
paediatricians. Children had probably permanent CH if confirmation of CH as defined above 
was absent but the clinician was continuing levothyroxine at final follow-up. Children were 
confirmed not CH if not on treatment by three-year follow-up; children who had a period on 
levothyroxine before treatment was discontinued, following a trial off therapy or other 
clinical evaluation (not specified by the clinician), were defined as transient CH.  
Test performance, incidence and standardised population 
Incidence of permanent CH diagnosis in UK infants was estimated, using monthly live birth 
data from the Office for National Statistics (ONS)9, National Registrations Scotland10 and 
Northern Ireland Registration and Statistics Authority, for England and Wales, Scotland and 
Northern Ireland respectively.11 Ethnic groupings were White, Asian, Black, Mixed and 
Other (UK Census 2011 categories).12 Incidence rates (IR) by sex, gestation and ethnicity 
were estimated for England only using ONS live birth data (n=693,748 live births; personal 
communication Professor Cortina-Borja13); incidence rate ratios (IRR) were estimated for 
comparison with reference categories (Table 2). Analyses comparing screen thresholds used 
standardised English live birth data13, adjusted for between-laboratory population differences 
by sex, gestation and ethnicity that could influence screening outcomes.4 
Performance of the UK newborn screening programme, in detecting confirmed/probably 
permanent CH, was evaluated from 2011 to 2012 (n=813,087 live births), after excluding 
four infants diagnosed before screening and four with indeterminate outcome. In separate 
sensitivity analyses, (i) children with probably permanent CH were assigned to the ‘not CH’ 
category and (ii) infants with indeterminate outcome were assumed to be all true or all false 
positive cases. 
Laboratories reported actual TSH values for positive screen results, and all values below 
the local threshold as ‘screen negative’, therefore a continuous receiver operating curve 
(ROC) could not be plotted to compare thresholds. Instead three groups of English screening 
laboratories were defined by the lower TSH threshold each used, Group 1 (n=5 laboratories; 
TSH≥5 or ≥6mU/L), Group 2 (n=3; TSH≥8mU/L) and Group 3 (n=4; TSH≥10mU/L), and 
screening performance compared between groups. As populations served by the laboratories 
differed in ethnic preterm birth rate profiles, we directly standardised populations14 for 
comparison. We applied screen positive rates by sex, ethnicity and gestation from each 
laboratory group to the English population of 693,748 live births and adjusted the results to a 
population of 100,000 infants. The trade-off between sensitivity and specificity for each 
laboratory group was plotted on a ROC of sensitivity versus false positive rate (1-specificity).  
Test performance at different TSH thresholds was compared by estimating positive 
(rLR+) and negative (rLR-) relative likelihood ratios, using the method described by Hayen15 
and assuming that a threshold of TSH≥6mU/L and TSH≥8mU/L were replacement screening 
thresholds for TSH≥10mU/L. Where the rLR+ for the new threshold is >1 compared with the 
current threshold, this indicates that the new threshold is more likely to correctly assign a 
positive screen result to a child with CH, while a rLR- for the new threshold of <1 indicates 
the new threshold is less likely to incorrectly assign a positive screen result to a child without 
CH.  
Statistical Analysis 
Statistical analyses were performed using StataSE13 (StataCorp, TX). Research ethics 
approval (Cambridge South REC; 11/EE/0152) and Section 251 support were obtained (ECC 
3-04(k)/2011).  
Results 
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There were 518 notifications from clinicians and 704 from laboratories. We excluded 75 
duplicates (cases reported twice through the same source), 118 diagnosed before 01 July 
2011 or not meeting our case definition (including non-UK births), and 41 cases that 
remained unverified as sufficient clinical details were not provided. Of those remaining, 338 
were ‘matched’ notifications reported by both laboratory and clinician sources.  
All further analyses are based on 650 individual cases reported to the study during 12 
months between 01 July 2011 and 30 June 2012, comprising 629 children investigated after a 
presumptive positive newborn screen result and 21 reported as ‘clinically detected’ by 
paediatricians. The total population screened was 813087 (Table 3), of which 1.5% babies 
were born <32 weeks gestation and followed the ‘preterm’ screening pathway which included 
a repeat whole blood sample (Table 1).  
Children reported following a presumptive positive screen result were more likely to be 
girls (n=367; 58.3%) and of White (n=369; 58.6%) or Asian (n=128; 20.3%) ethnicity. Fifty 
(7.9%) babies were born <32 weeks gestation. Twelve deaths occurred and all were 
associated with prematurity or comorbidities; one infant was being treated for CH, 10 did not 
have CH, and one died before diagnostic tests were completed.  
Of 21 clinically detected children,11 were girls, 11 were of White ethnicity and six were 
born <32 weeks gestation; one death occurred which was unrelated to CH. CH was not 
suspected at newborn screening in 17 (‘screen negative’) of these children and four were 
referred for investigation before the screening results were available; we refer to all of these 
as ‘clinically detected’ cases as they were not identified through the newborn screening 
pathway. 
Diagnostic outcomes 
Infants with a presumptive positive screen 
At initial clinical referral (ICR), 488 (77.6%) of 629 children were diagnosed with CH and 
commenced levothyroxine; CH was excluded in 137 (21.8%) infants (Figure 1a). Diagnostic 
tests remained incomplete in four children (indeterminate outcome), one of whom died.  
By three years of age, 295 children had confirmed permanent CH, of whom 33 had a trial 
off therapy, 165 had scan confirmation of agenesis or ectopic thyroid, and 97 required high 
dose levothyroxine. A further 123 children had probably permanent CH. CH was excluded in 
207 children (trial off therapy (n=58) or other clinical evaluation [n=149]; Figure 1a), of 
whom 70 received thyroxine for <3 years (transient CH). Of 50 screen positive babies born 
<32 weeks gestation, 16 had confirmed/probably permanent CH at 3 years. 
Clinically detected children 
At ICR, 20 of 21 children were diagnosed with CH and started levothyroxine; CH was 
excluded before treatment in one (Supplementary Table S4). Six children were born <32 
weeks gestation and had a repeat screen, and five were born between 32 weeks and <37 
weeks gestation. Four children suspected before screening had comorbidities and/or family 
history and all remained on treatment at 3 years. Two of these babies had a blood spot 
TSH≥10mU/L screening (20 and 40mU/L) however they were referred before these 
screening results were reported.  
By three year follow-up, four children had confirmed permanent CH; three of these had a 
trial off therapy and one required high dose thyroxine (Figure 1b). These children presented 
with a congenital anomaly, family history or prolonged jaundice; all had bloodspot TSH 
<8mU/L and started levothyroxine by age three months. Ten children had probably 
permanent CH at 3 years; all bloodspot TSH were ≤8mU/L (and <6mU/L in seven children). 
Four of six babies born <32 weeks gestation had confirmed/probably permanent CH at 3 
years. CH was excluded in seven children by 3 years; six had transient CH (confirmed by 
trial off therapy [n=3] or other clinical evaluation [n=3]) and one never started treatment. 
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Incidence of CH 
There were 432 infants born between 1st July 2011 and 30th June 2012 and subsequently 
diagnosed with confirmed/probably permanent CH (418 with a positive screen [Figure 1a] 
and 14 clinically detected [Figure 1b]); no child presenting after age one year had 
confirmed/probably permanent CH. UK birth prevalence was 5.3 (95% CI: 4.8, 5.8) per 
10,000 live births.  
Incidence of permanent CH by sex, gestation and ethnicity was estimated for English live 
births (Table 2). Incidence of permanent CH was significantly higher for girls (IRR 1.5 [1.2, 
1.8]), and for infants born before 32 weeks gestation compared with those born at or after 32 
weeks (IRR 3.7 [2.2, 5.9]). Compared to children of White ethnicity (IR 4.5 [95%CI: 4.0, 
5.1]), children of Asian and Chinese ethnicity had a significantly higher incidence of 
permanent CH (IRR: Asian 2.5 [1.9, 3.2], Chinese 4.2 [1.7, 8.7] respectively), while children 
of Black ethnicity had lower incidence (IRR 0.4 [0.1, 0.8]).  
Screening programme performance 
Evaluation of UK-wide screening programme performance, using locally-determined TSH 
thresholds, demonstrated high sensitivity 96.76% (95% CI: 94.62%, 98.22%) and specificity 
99.97% (95% CI: 99.97%, 99.98%), for a PPV of 66.88% (95% CI: 63.04%, 70.56%; Table 
3). The likelihood ratio for a positive screen result (LR+), or the odds of a child having 
permanent CH if the screening test is positive, was high at 3799. Sensitivity analyses 
assigning children with probable CH to ‘not CH’ demonstrated similar screening sensitivity 
(95.47% [95%CI 92.54%, 97.28%]) and specificity (99.96% [95%CI 99.95%, 99.96%]) but 
lower PPV (47.20% [95%CI 43.32%, 51.12%]). Sensitivity analyses re-assigning infants with 
indeterminate outcomes did not significantly alter test performance (data not shown).  
Screening performance at different bloodspot TSH thresholds 
Screening performance at three TSH thresholds used by different groups of English 
laboratories (≥6mU/L, ≥8mU/L, ≥10mU/L) was compared for a population of 100,000 
English live births standardised by sex, gestation and ethnicity (Supplementary Table S1). At 
TSH thresholds lower than the national standard (≥10mU/L), the sensitivity and false positive 
rate increased, and PPV decreased, being 62.2% at ≥6mU/L. 
A plot of sensitivity and specificity for each laboratory group (Figure 2) suggests that the 
optimal TSH threshold lies between ≥6 and ≥10mU/L. This was supported by the positive 
(rLR+) and negative (rLR-) relative likelihood ratios estimated for screening test performance 
at TSH≥6mU/L and TSH≥8mU/L, compared with TSH≥10mU/L (Table 4). Compared with a 
TSH threshold ≥10mU/L, the rLR+ value of ≥8mU/L was >1 and rLR- was <1. As 95% CI 
for rLR+ included 1, we cannot exclude the possibility that TSH≥8mU/L does not differ 
significantly from the current national standard (TSH≥10mU/L)15, nevertheless these results 
suggest that the NPV for ≥8mU/L is superior to ≥10mU/L without appreciable reduction in 
PPV. In contrast, the rLR+ and rLR- were <1 for TSH≥6mU/L, suggesting the PPV at 
TSH≥6mU/L is inferior to ≥10mU/L. Sensitivity analyses reassigning ‘probably permanent’ 
CH cases to ‘not CH’ did not change the rLR- values but, compared with TSH≥10mU/L, the 
rLR+ for TSH≥8mU/L reduced to 1.02 (95% CI 0.76, 1.37) and the TSH≥6mU/L remained 
<1 (rLR+ 0.66 [95% CI 0.51, 0.84]).  
Had all English laboratories in this study been using TSH≥10mU/L, 10 children with 
confirmed permanent CH screened in laboratories using thresholds between TSH≥6 mU/L 
and <10mU/L, might have been ‘missed’ (Supplementary Table S3). At a threshold 
TSH≥8mU/L, six children would have been screen positive, while the remaining four infants 
had bloodspot TSH values <8mU/L (one had a congenital syndrome associated with CH, and 
three had dyshormonogenesis with normal scans).  
Discussion 
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In a prospective UK-wide study of CH using active reporting by clinicians and newborn 
screening laboratories, we found that only two-thirds of those with an initial diagnosis of CH 
following a presumptive positive screening result continued to require thyroxine treatment 
three years later. We estimate that, in England, CH incidence is higher in girls, babies born 
<32 weeks gestation or of Asian or Chinese ethnicity, and overall higher than before 
screening was introduced. Our evaluation of screening programme performance 
demonstrated that the UK programme has high sensitivity, specificity and positive predictive 
value. Importantly we have shown that replacing the national recommended threshold of 
TSH≥10mU/L with a lower threshold of TSH≥8mU/L would likely result in improved test 
performance and identify infants who are currently detected at thresholds below the current 
recommended threshold, without concomitant increase in false positive screening results. 
We found no substantial advantage in test performance using a threshold of TSH≥6mU/L. 
Importantly, these thresholds are in relation to the UK screening programme, in which the 
newborn bloodspot is taken at 5 days of age, and therefore these thresholds may not apply 
to programmes that perform screening earlier or later. 
We identified a contemporary incidence of CH that is approximately double that reported 
in the UK population before newborn screening was introduced,16 similar to the increase 
noted with  introduction of screening in other European and north American countries.1,17 
This rise may be related to changes in population demographics1,18 and, in the UK, ethnic 
variation in thyroid physiology has been proposed as underlying the growth in screen-
detected cases.4 Schoen has highlighted variations by sex and ethnicity in the population 
distribution of mild and severe CH, which may reflect different causes.19 As maternal iodine 
insufficiency leads to raised newborn TSH, higher rates of positive screen results may be 
partly due to increased prevalence of insufficiency amongst UK women5,6; this merits further 
investigation. 
Lower TSH thresholds may also contribute to the observed increase in CH incidence 
through increased detection of ‘transient’, mild or subclinical CH; the implications for 
neurodevelopmental outcomes and need for lifelong treatment are less clear for these 
children.20,21 Alm reported that children with subclinical CH, defined as raised TSH without 
other symptoms and signs of CH, had similar neurodevelopmental outcomes to unaffected 
controls.22 More recently, Lain23 showed that children with marginally raised newborn TSH 
results, below the levels indicated for treatment in the Australian programme, perform less 
well educationally than children with treated CH or with negative screen results at lower TSH 
levels, suggesting the potential for subtle cognitive impairment due to mild CH.  
However lower thresholds lead to significant increases in false positive rates.20,24 
Korada24 reported 126% increase in false positive rate on lowering the TSH threshold from 
20mU/L to 6mU/L. Furthermore the investigation of false positive results increases the costs 
of screening25,26, and can lead to persisting anxiety in parents even after exclusion of CH.27,28 
Children treated for mild or severe CH may experience reduced quality of life29 compared 
with unaffected peers, and neurodevelopment may be adversely affected by frequent 
monitoring which raises concerns for parents and children.30 The harms of over-investigation 
and over-treatment, including the continuing treatment lifelong in children for whom CH is 
not confirmed, are significant and should not be ignored when evaluating newborn 
screening. 
As in our study, Ford found that US newborns who were identified as presumptive 
positive CH on the first bloodspot were more likely to be girls and to have permanent CH 
than those who were referred on a repeat test.17 He suggests that the first test may identify 
infants with prenatal onset of CH due to agenesis or ectopic thyroid, which are more 
common in girls.  
False negative rates in our study were higher than those reported previously7, however 
these are likely to have been underestimated in previous studies which used less reliable 
methods for ascertaining clinically presenting cases. Two studies31,32 using multiple sources 
to capture false negative cases reported rates of 0.1 and 0.3 per 100,000 respectively, which 
compares with our rate of 1.1 per 100,000 infants screened. These false negative or ‘missed’ 
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cases underline the importance of checking thyroid function in older infants who present with 
clinical manifestations that may indicate hypothyroidism, as inevitably not all cases can be 
detected by population screening programmes even when very low TSH thresholds are used. 
Important strengths of our observational study were the complete national coverage of a 
large population of over 800,000 newborns in which all screening laboratories were using 
AutoDELFIA (Perkin Elmer) technology, and high ascertainment and follow up rates. 
Moreover the high rate of ascertainment of clinically presenting screen-negative cases, 
permits reliable estimates of screening programme performance. Nevertheless the 
laboratory source was essential for achieving complete ascertainment, as some 
paediatricians did not report all cases identified as presumptive positive by screening. 
Paediatricians were more likely to report a screen positive infant if they started treatment, 
whereas laboratory staff reported all screen positive infants regardless of subsequent 
treatment decisions.  
Although differences in screening thresholds between laboratories introduced variability 
into our estimates of sensitivity and specificity for the screening programme as a whole, we 
were able to take advantage of these to evaluate the influence of bloodspot TSH thresholds 
on screening performance. Furthermore using direct population standardization, we ensured 
that differences between the three laboratory groups, including population ethnicity, were 
accounted for in our comparative analyses.  
Unlike many previous studies, we undertook follow-up to three years after initial referral 
and obtained information about re-evaluation and confirmatory tests throughout this period 
to inform the final assignment of diagnostic outcome. Had we relied upon the diagnosis at 
onset of therapy, the estimated number of CH cases would have been 16% higher. However 
as this was an observational study, clinicians completed questionnaires using only the data 
that was routinely available in medical records therefore information about the reasons for 
clinical decisions was limited. We assumed at three-year follow-up that children who 
continued on a levothyroxine dose of <50mcg per day without re-evaluation or scan 
confirmation had probably permanent, rather than transient, CH: should this assumption 
prove incorrect, this would result in under-estimation of transient cases and over-estimation 
of probably permanent CH cases.  
Our study demonstrates that, in the UK, 30% of children with a presumptive positive 
screen continue long-term on thyroxine treatment without a trial off therapy or other 
confirmation of permanent CH. This underlines the need for a more active approach to re-
evaluating CH diagnosis in all children around 2-3 years of age to avoid lifelong 
levothyroxine in children who do not require it.  
Analysis of the trade-off between sensitivity and specificity at screening thresholds of ≥6, 
≥8 and ≥10mU/L suggests that the optimal TSH threshold is likely to be around 8mU/L for 
infants screened at 5 days of life. A reduction in screen test thresholds that completely 
avoids ‘missed’ cases is not feasible and would likely result in a higher numbers of children 
undergoing unnecessary investigation and treatment for CH. Most children in our study who 
presented clinically after a negative screen result were identified through investigation of 
prolonged jaundice or comorbidities.  
Existing cost-benefit analyses for the UK screening programme for CH are based on 
preventing severe intellectual disability33, however there is no clear evidence that these 
benefits apply to all types of CH, including children identified at lower screen thresholds. 
Further investigation of the natural history and benefits of treating mild, transient or 
subclinical CH is essential to confirm the benefit or otherwise of extending the current 
screening programme to detect such cases. Further research is essential to understand the 
characteristics and outcomes for infants with mild or transient CH in order to offer an 
effective population screening programme that appropriately balances the benefit of early 
diagnosis against the harms of over-investigation and over-treatment. 
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Figure 1: Flow diagram of outcomes at initial clinical referral and three year follow-up: (a) 
for 629 babies referred as screen positive; (b) for 21 babies referred as clinically detected 
Figure 2: Receiver Operating Curve by English laboratories grouped according to TSH 
screening thresholds used 
Table 1: Screening and Surveillance Definitions* 
The first newborn bloodspot sample is taken at 5 days of age in all babies.  
Babies born at less than 32 weeks gestation also have a second (repeat) bloodspot sample at 28 days of age or on the day of discharge 
home, whichever is sooner, as immaturity may mask CH. 
A presumptive positive screening result requiring referral for diagnostic investigation is defined as a TSH concentration of >20mU/L on 
the newborn blood spot (whole blood) sample; a concentration between 10 and 20 mU/L is a ‘borderline’ result requiring a repeat screen 
and diagnostic referral if the TSH level remains ≥10mU/L in the second blood spot sample. 
Clinical referral guidelines recommend thyroid function tests (serum TSH and free T4) to confirm the diagnosis after a presumptive 
positive screen as well as ultrasound and/or radio-isotope scans to determine the underlying thyroid gland abnormality.5  
Treatment – oral thyroxine which should be initiated by 21 days of age.2,5 
--------------------------------------- 
Reporting Case definition: 
Any child up to and including five years of age who, during the past month, has been referred:  
• EITHER for diagnostic confirmation following a newborn screening test result suggestive of primary congenital 
hypothyroidism (CH),  
• OR has been confirmed with a diagnosis of primary CH (known or considered likely to be present from birth), based on a 
serum TSH≥10mU/l.  
Table 2: Annual incidence of diagnosis of CH per 10,000 live births in England 
 
Confirmed/ Probable 
CH (n) Births (n) in England* 
Incidence (95% CI) per 
10,000 live births Rate ratio
§
 (95% CI) 
Sex  
Male 148 338,081 4.4 (3.7, 5.1) reference 
Female 227 355,667 6.4 (5.6, 7.3) 1.5 (1.2, 1.8) 
Not known 0 2592 - - 
Gestation at birth  
≥32 weeks 354 683,829 5.2 (4.7, 5.7) reference 
<32 weeks 19 9,919 19.2 (11.5, 29.9) 3.7 (2.2, 5.9) 
Not known 2 2592 - - 
Ethnicity  
White 231 510,586 4.5 (4.0, 5.1) reference 
Asian 82 73,466 11.2 (8.9, 13.9) 2.5 (1.9, 3.2) 
Black 6 36,264 1.7 (0.6, 3.6) 0.4 (0.1, 0.8) 
Mixed 23 34,969 6.6 (4.2, 9.9) 1.5 (0.9, 2.2) 
Chinese 7 3,724 18.8 (7.6, 38.7) 4.2 (1.7, 8.7) 
Other 12 13,484 8.9 (4.6, 15.5) 2.0 (1.0, 3.5) 
Not known 14 23,847 - - 
Notes * Denominators are from 693,748 live births in England by sex, ethnicity and gestation between July 
2011 and June 2012 (data provided by Professor M Cortina-Borja); the numerator is 375 probable/confirmed 
CH cases in England only (as these denominators were not available for Scotland, Northern Ireland and Wales). 
§ The incidence rate ratio is estimated for the incidence rate within each category compared with the reference. 
Abbreviations CH congenital hypothyroidism; n number; CI confidence intervals 
Table 3: Performance of the UK newborn screening programme for CH, 2011-2012 
 Confirmed/Probable CH (n) CH excluded (n) Total 
Screen positive* 418 207 625 
Screen negative* 14 812448 812462 
Total (n) 432 812655 813087 
Screening performance 
Sensitivity (%; 95%CI) 96.76% (94.62%, 98.22%) 
AD
VA
N
CE
 A
RT
IC
LE
:
TH
E 
JO
UR
NA
L 
O
F 
CL
IN
IC
AL
 
EN
D
O
CR
IN
O
LO
G
Y 
& 
M
ET
AB
O
LI
SM
JC
EM
Downloaded from https://academic.oup.com/jcem/advance-article-abstract/doi/10.1210/jc.2018-00658/5063511
by University of Newcastle user
on 06 August 2018
AD
VA
NC
E 
AR
TI
CL
E
The Journal of Clinical Endocrinology & Metabolism; Copyright 2018  DOI: 10.1210/jc.2018-00658 
 
 
11
Specificity (%; 95%CI) 99.97% (99.97%, 99.98%) 
Positive predictive value (PPV; %; 95%CI)  66.88% (63.04%, 70.56%) 
False positive rate (%; 95%CI) 0.03% (0.02%, 0.03%) 
Likelihood ratio positive (LR+) 3799  
Likelihood ratio negative (LR-) 0.03  
*Screen result as defined by local laboratory TSH thresholds; outcome as defined at 3 year follow-up. 
Abbreviations CH congenital hypothyroidism; n number; CI confidence intervals 
Table 4: Relative likelihood ratios for screen thresholds replacing TSH≥10mU/L 
TSH≥6mU/L as a replacement for TSH≥10mU/L* 
 LR+ LR- 
Existing test (TSH ≥10mU/L) (Groups 2&3; 
n=377,914) 5303.00 0.16 
Replacement test (TSH ≥6mU/L) (Group 1; 
n=315,944) 2773.00 0.02 
rLR+ 0.52 (95%CI 0.38, 0.72) 
rLR- 0.11 (95%CI 0.03, 0.36) 
TSH≥8mU/L as a replacement for TSH≥10mU/L** 
 LR+ LR- 
Existing test (TSH ≥10mU/L) (Group 3; 
n=252,028) 5632.00 0.16 
Replacement test (TSH ≥8mU/L) (Groups 
1&2; n=441,830) 4691.00 0.02 
rLR+ 1.20 (95%CI 0.82, 1.75) 
rLR- 0.11 (95%CI 0.06, 0.20) 
Notes * Screen performance was estimated for all children in Laboratory Group 1 (TSH≥6mU/L) and compared 
with all children in Laboratory Groups 2 and 3 combined (using TSH≥10mU/L as the screen thresholds); ** 
Screen performance was estimated for all children in Laboratory Groups 1 and 2 combined (using TSH≥8mU/L 
as the screen thresholds and treating all values below this as negative)  and compared with all children in 
Laboratory Group 3 (TSH≥10mU/L); Abbreviations TSH thyroid stimulating hormone; CH congenital 
hypothyroidism; CI confidence interval; LR+ likelihood ratio for a positive screen result; LR- likelihood ratio 
for a negative screen result; rLR+ positive relative likelihood ratio; rLR- negative relative likelihood ratio;  
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(a)
(b)
Notes * Trial off therapy: a period of withdrawal of thyroxine replacement therapy to allow re-evaluation 
of thyroid function tests off therapy and confirmation of permanent or transient CH.
Abbreviations CH congenital hypothyroidism; 
21 clinically 
detected 
babies referred 
Trial off 
therapy* n=6 
Clinician 
diagnoses CH 
n=21 
CH excluded 
by clinician  
n=4 
Initial clinical referral Three year outcome 
Confirmed CH  
(trial-off n=3; dose 
confirmed n=1) 
n=4 
Probable CH  
(clinician treating) n=10 
CH excluded 
by trial-off thyroxine 
n=3 
Not CH 
n=7 
CH 
n=14 
629 screen 
positive babies 
referred 
Clinician 
excludes CH  
n=137 
Trial off 
therapy* n=91 
Clinician 
diagnoses CH 
n=488 
Diagnostic tests 
incomplete n=4 
CH excluded 
by clinician  
n=149 
Initial clinical referral Three year outcome 
Confirmed CH  
(trial-off n=33; scan/
dose confirmed n=262) 
n=295 
Status unknown 
n=4 
Probable CH  
(clinician treating) 
n=123 
CH excluded 
by trial-off thyroxine 
n=58 
Not CH 
n=207 
CH 
n=418 
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